Stock Analysis
Pfizer Inc.PFE
P/E 38.90×· 5Y range 7.12–40.46×· top 1% of history
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsHold36 analystsP/E 38.9× sits at the 99th percentile of its 5.0978781656399725-year history.
Cash covers 18% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Quality72
- Financial Health60
Risks
- Valuation65
- Growth25
Mixed fundamentals at a demanding price.
What's happening with PFE
Profile
growth lags behind.
How is each axis scored?
- Valuation65/100 · Moderate
- P/E vs own history (99th pct)0/25
- FCF yield (6.5%)20/25
- P/S (2.6x)20/25
- EV/EBIT (10.0x)25/25
- Growth25/100 · Weak
- Revenue CAGR (-6.3%)0/25
- Net income CAGR (-22.9%)0/25
- EPS CAGR 5Y (-22.9%)0/25
- Fwd implied growth (306.2%)25/25
- Profitability55/100 · Moderate
- ROIC (12.7%)12/25
- ROE (5.1%)5/25
- Net margin (6.8%)13/25
- Operating margin (34.7%)25/25
- Financial Health60/100 · Moderate
- Altman Z (2.00)18/25
- Current ratio (1.27)12/25
- Interest coverage (5.0x)18/25
- Net cash / debt (D/A 26%)12/25
- Quality72/100 · Moderate
- Piotroski F (4/9)10/25
- Beneish M (-2.68)25/25
- FCF conversion (253%)25/25
- Margin stability (σ 8.3%)12/25
- Moat68/100 · Moderate
- ROIC >12% years (3/10 yrs)6/25
- Median gross margin (75.5%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 3.6%)12/25
Risk Flags
- ⚠Revenue shrinking 6.3%/yr
- ⚠P/E 38.9× at top 1% of 5-year history
About Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. Show more
While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Headquarters: NEW YORK, NY · Employees: 75,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
65BP/E (TTM)38.9xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 7.1x–40.5x · highest in history
P/FCF15.4xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.5%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.7%–12.7% · 38th pct
P/S (TTM)2.65xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.0x–5.5x · 62nd pct
EV/EBIT10.0xA
Grade A: CheapEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 7.0x–58.9x · 32nd pct
EV/Sales3.6xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E9.6xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.97xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-5.20A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield5.78%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio80.3%C
Grade C: HighDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
55CROIC12.7%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE5.1%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA2.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin6.8%C
Grade C: AverageNet Income / Revenue
Operating Margin34.7%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin73.2%A
Grade A: PremiumGross Profit / Revenue
FCF Margin17.2%A
Grade A: HighFCF / Revenue
True FCF Margin15.8%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR-6.3%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-22.9%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-22.9%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth306.2%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+0.5%B
Grade B: FlatShare count change over 5Y
SBC / Net Income21.9%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.5%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
60BAltman Z-Score2.00C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.27xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.96xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage5.0xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment4.7yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT2.3xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.74xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.18xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
72B+Piotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.68A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion253.5%A
Grade A: StrongFCF / Net Income
Margin Stability8.3%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue3.8%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.31xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
BOURLA ALBERT Filed | BOURLA ALBERT | Grant / award | +71 | |
BOURLA ALBERT Filed | BOURLA ALBERT | Grant / award | +21 | |
Buckley Mortimer J Filed | Buckley Mortimer J | Grant / award | +1.3K | |
Echevarria Joseph Filed | Echevarria Joseph | Grant / award | +1.6K | |
SMITH JAMES C Filed | SMITH JAMES C | Grant / award | +1.6K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Quincey James Filed | Quincey James | Grant / award | +1.4K | |
Taraporevala Cyrus Filed | Taraporevala Cyrus | Grant / award | +1.3K | |
NARAYEN SHANTANU Filed | NARAYEN SHANTANU | Grant / award | +1.7K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years3/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)75.5%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor3.6%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$0.76
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.05
Cash & short-term investments per share (Finnhub)
Book Value / Share$14.95
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$63.48B
Total debt obligations (short + long term)
Cash & Equiv.$11.70B
Cash and short-term investments
Net Debt$51.78B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$85.49B
Shareholders' equity (book value)
Asset / Liability1.74xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$168.60B
Current Market Capitalization
Beta0.31B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Pfizer Inc. (PFE)
Piotroski F-Score of 4/9 indicates mixed fundamentals for Pfizer Inc.. Altman Z-Score of 2.00 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.68 suggests a low likelihood of earnings manipulation. Revenue has been contracting (CAGR ≈ -6%), which weighs on the growth outlook.
- Pfizer Inc. converts about 17% of revenue into free cash flow — strong cash generation.
- Takes ~4.7 years to repay net debt from free cash flow.
- The stock currently yields 5.8% in dividends.
See how PFE ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all PFE moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 29.23 | +3.01% | 3.12 |
| Oct 14 | After-hours | 29.20 | +2.93% | 3.03 |
| Oct 7 | Regular | 28.02 | +1.87% | 2.65 |
| Oct 7 | After-hours | 28.02 | +1.90% | 2.68 |
Frequently Asked Questions about PFE
What is the current Pfizer Inc. (PFE) stock price?
PFE is trading at $29.58 at the last market close, up 0.48% on the session. PreMarketPrice tracks PFE pre-market, intraday and after-hours prices.
Is PFE stock a buy right now?
PreMarketPrice's quantitative model rates Pfizer Inc.'s financial health at 60/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is PFE stock overvalued?
Pfizer Inc. trades at a trailing P/E of 38.9 and our valuation score rates it 65/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Pfizer Inc. report earnings?
No confirmed earnings date is currently scheduled for PFE. The Earnings section lists recent reports and updates as dates are announced.
What sector does Pfizer Inc. operate in?
Pfizer Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does Pfizer Inc. do?
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion.
About Pfizer Inc. (PFE) Stock
Pfizer Inc. (PFE) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, Pfizer Inc. is trading at $29.58, up 0.48% on the day with a market capitalization of $168.6 billion. The financial health score for PFE is 60/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for PFE stock.
PFE Stock Analysis & Key Metrics
On PreMarketPrice, you can track Pfizer Inc. (PFE) across multiple dimensions:
- Pre-market price & movement: Real-time PFE stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for PFE with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Pfizer Inc. across multiple reporting periods.
- Financial health score: A composite score of 60/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for PFE.
- Sector peers: Compare PFE against 6 other healthcare stocks on key financial metrics.
Is PFE a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Pfizer Inc. (PFE) as an investment. The financial health score of 60/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Pfizer Inc. (PFE) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.